HomeENGLISH MAGAZINEVenous embolism and blood ties: "dawning" the needle onto A, B an...

Venous embolism and blood ties: “dawning” the needle onto A, B an AB while 0 gets twilight

Venous thromboembolism (VTE), or blood clots in the veins, is a leading cause of preventable hospital deaths worldwide. Venous thromboembolism includes deep vein thrombosis, a blood clot that typically forms in the deep veins of the leg, and pulmonary embolism, which occurs when a blood clot breaks free and lodges in the arteries of the lung. Although these blood clots can affect anyone, existing research suggests that those with blood types other than 0 are more likely to develop VTE. Cancer and cancer therapies also increase the chances of developing blood clots, and although people with severe forms of cancer are more likely to develop VTE, there is less research on the risk among patients with cancers less associated with thrombosis. Existing assessments use factors such as the tumor or type of cancer to detect those at high risk for VTE. However, many patients without these diagnoses still develop life-threatening blood clots but are not identified.

New research now presented in the journal Blood Advances suggests that people with cancer and non-0 blood groups, such as types A, B, and AB, are at an increased risk of developing venous thromboembolism three months after initial diagnosis. Scientists have long sought to understand the risk factors for VTE. Although the type of cancer can be useful in identifying people who are more likely to develop VTE, many people with less severe cancers still have dangerous blood clots and therefore may require additional monitoring and treatment. The study results suggest that blood typing may serve as another important predictive measure. In the study, the researchers investigated the role of non-0 blood groups in participants’ likelihood of developing VTE. They collected data from 1,708 adult participants with a new or recurrent cancer diagnosis from the Vienna Cancer and Thrombosis Study (CATS) dataset.

The researchers grouped the participants first by blood type, then sorted them by tumor classification. Patients with pancreatic, gastroesophageal, and brain cancer were considered to be high-risk diagnoses. Their results indicated that patients with non-0 blood types were more likely to develop VTE three months after their cancer was diagnosed or returned. According to the researchers, this association did not appear at the time of diagnosis because anticancer therapies increase the likelihood of patients developing blood clots, making blood type a less significant predictor of VTE during the early stages of treatment. Those with cancers outside the high-risk disease category with non-O blood group were more likely to develop blood clots regardless of time, demonstrating that reliance solely on the type of tumor to detect the risk of VTE can cause the fall of many patients.

Therefore, non-0 blood group is a time-dependent predictor of VTE in cancer patients. It is associated with an increased risk of VTE beyond 3 months of follow-up and in patients with intermediate and low-risk cancer types. Another research team investigated the frequency of ABO blood group genotypes in the pulmonary embolism patient population and the severity index score (PESI) for specific ABO blood group genotypes. The survey observed a significantly higher frequency of the A1B and BB genotypes in patients with pulmonary embolism than in healthy individuals, while the O1O1 genotype was significantly less frequent in patients. Analyzing the severity of the clinical presentation based on the PESI score, we did not find a correlation between the severity of the clinical presentation and a given blood group genotype. Thus, in addition to VTE, non-0 blood groups may also are at increased risk for pulmonary embolism.

Going forward, the investigators also aim to better understand the biological mechanisms underlying these findings. They hope that blood typing can serve as a useful biomarkers in risk assessments for cancer-associated and cardiologic embolism in the future.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Englisch C et al. Blood Adv 2022 Apr 13:bloodadvances.2021006283.

Wang H et al. Res Pract Thromb Haemost. 2022 Mar 1; 6(2):e12671.

Moik F et al. .Arterioscler Thromb Vasc Biol. 2021; 41(11):2837-2847.

The following two tabs change content below.

Dott. Gianfrancesco Cormaci

Medico Chirurgo, Specialista; PhD. a CoFood s.r.l.
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento enzimaticamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (Leader of the R&D for the partnership CoFood s.r.l.) - Autore di articoli su informazione medica e salute sul sito www.medicomunicare.it (Medical/health information on website) - Autore di corsi ECM FAD pubblicizzati sul sito www.salutesicilia.it
- Advertisment -